Rationale and design of a multicentre, randomized, placebo‐controlled trial of mirabegron, a Beta3‐adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3‐left ventricular hypertrophy (Beta3‐LVH)

AIMS: Progressive left ventricular (LV) remodelling with cardiac myocyte hypertrophy, myocardial fibrosis, and endothelial dysfunction plays a key role in the onset and progression of heart failure with preserved ejection fraction. The Beta3‐LVH trial will test the hypothesis that the β(3) adrenergi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pouleur, Anne‐Catherine, Anker, Stefan, Brito, Dulce, Brosteanu, Oana, Hasenclever, Dirk, Casadei, Barbara, Edelmann, Frank, Filippatos, Gerasimos, Gruson, Damien, Ikonomidis, Ignatios, Lhommel, Renaud, Mahmod, Masliza, Neubauer, Stefan, Persu, Alexandre, Gerber, Bernhard L., Piechnik, Stefan, Pieske, Burkert, Pieske‐Kraigher, Elisabeth, Pinto, Fausto, Ponikowski, Piotr, Senni, Michele, Trochu, Jean‐Noël, Van Overstraeten, Nancy, Wachter, Rolf, Balligand, Jean‐Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165933/
https://www.ncbi.nlm.nih.gov/pubmed/29932311
http://dx.doi.org/10.1002/ehf2.12306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165933/
https://www.ncbi.nlm.nih.gov/pubmed/29932311
http://dx.doi.org/10.1002/ehf2.12306

Ejemplares similares